Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03995121

SV2 PET Imaging With [11C]APP311

Sponsor: Yale University

View on ClinicalTrials.gov

Summary

The aim of this study is to evaluate a new SV2A tracer, \[11C\]APP311, in healthy aging and neuropsychiatric disorders including psychotic disorders and cannabis use disorders.

Official title: Synaptic Density in Psychiatric Disorders Using SV2A Receptor PET Imaging With [11C]APP311

Key Details

Gender

All

Age Range

18 Years - 85 Years

Study Type

OBSERVATIONAL

Enrollment

250

Start Date

2017-12-01

Completion Date

2026-12

Last Updated

2026-01-28

Healthy Volunteers

Yes

Interventions

DRUG

[11C]APP311

It has been shown that radiotracer \[11C\]APP311 (aka \[11C\]UCB-J) displays high specificity and selectivity for the synaptic vesicle protein SV2A. Since this protein is expressed ubiquitously in active synapses, this tracer has the potential to be a general purpose tool for quantitative imaging of synaptic density.

Locations (1)

Conneticut Mental Health Center

New Haven, Connecticut, United States